pharmaphorum
FEBRUARY 1, 2022
David Clifton is professor of clinical machine learning in the Department of Engineering Science of the University of Oxford. His research focuses on the development of big data machine learning for tracking the health of complex systems. Mark holds a PhD in biomedicine, and an MSc in biostatistics.
pharmaphorum
FEBRUARY 11, 2022
In 2021, Komodo acquired two companies: Mavens, a developer of cloud-based software used for speciality biotech and pharma companies, and Breakaway Partners, a market access software company targeting the life sciences industry. He oversees operations, including business development, sales and marketing, and people.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
MAY 30, 2022
He oversees operations, including business development, sales and marketing, and people. He also serves as an executive advisor to Reify Health, Heads Up Health , and other healthcare/healthtech start-ups focused on big data, SaaS, healthcare IT (HIT), and predictive analytics to improve patient outcomes.
XTalks
AUGUST 2, 2023
They are committed to capitalizing on growth opportunities primarily through the advancement of their own product pipeline and constantly improving their existing products, as well as through business development activities. 2022 Revenue: In 2022, Merck KGaA (Life Science and Healthcare divisions only) had an annual revenue of €18.22
Drug Discovery World
SEPTEMBER 6, 2022
This will be driven in a major way through breadth of ongoing research and an increased move to better tolerated, logistically simpler allogeneic platforms, such as the optimized Natural Killer (NK) cell therapies being developed at ONK Therapeutics. Chris Nowers, CEO, ONK Therapeutics. . “ VÃctor Cervera-Carrascón, Tilt Bio. .
Expert insights. Personalized for you.
86 
Let's personalize your content